AGN
ARGENICA FPO [AGN]
Healthcare · ASX Small Cap
$0.1400 +0.0%
Updated 14 Jul 2026 · Signals refresh every scan
Get alerts when AGN triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Pressing against the upper Bollinger Band — extended and may need to cool off
- On a tear — up 33.3% over the last 5 days
- Beating the Small Ords index — relative strength of 1.37, so it's outpacing the pack
- Volume-price trend suggests distribution — sellers may be sneaking out while price holds
- Low cash runway (2 quarters) - dilution risk
- Revenue in sharp decline (-78%)
- Near 52-week low (8% of range)
- Micro-cap ($5-20M) - high risk
- Sentiment is mixed — no strong consensus either way
- This one has been in freefall — down 66% over the past year
- Altman Z-Score distress zone (0.35 < 1.81, low-confidence approx)
- RBA hiking (-3pts)
Risk Signals
- Stochastic is stretched into overbought — could need a breather
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Revenue declining at -78% — the top line is shrinking
- The bigger volume days are the down days — volume-weighted momentum is negative (-1.03%/day)
Ask Scout AI about AGN
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE Investor Webinar
NONE ARG007 (Xaranetide) Completes All Three FDA Requested Assays
NONE WHO Confirms Xaranetide as INN for ARG-007
LOW Investor Presentation
Recent ASX Announcements
| 2026-06-10 | Investor Webinar |
| 2026-06-10 | Investor Presentation |
| 2026-06-10 | ARG007 (Xaranetide) Completes All Three FDA Requested Assays PRICE SENSITIVE |
| 2026-06-09 | WHO Confirms Xaranetide as INN for ARG-007 PRICE SENSITIVE |
| 2026-06-09 | Notification of cessation of securities - AGN |
Key Metrics
$18.0M
Market Cap
502K
Avg Volume
0.7x
Vol Ratio
$0.09 — $0.77
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-117.8%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 75% |
| L | Leader vs Laggard | laggard | RS: -12 |
| I | Institutional Sponsorship | weak | Inst: 1% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
109 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track AGN and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required